Novartis (SWX:NOVN) in Polaris Global Value Fund Q2 2024

Forecast Raised on Strong Sales of Heart Disease and Psoriasis Medicines

Apr 15, 2025

Summary

Raised forecast due to strong sales of blockbuster medicines for heart disease and psoriasis.
Stock saw its biggest boost in nine months.
Risks include patent expirations and regulatory challenges.
Contributed positively to the fund's healthcare sector performance.
Future outlook is positive with continued strong sales and strategic focus on key medicines.

In the Polaris Global Value Fund's 2nd-Quarter Letter 2024 Q2, Novartis (SWX:NOVN, Financial) was highlighted for its strong performance, driven by robust sales of its blockbuster medicines for heart disease and psoriasis. The Swiss pharmaceutical company raised its forecast, resulting in the stock's biggest boost in nine months.

"Swiss pharma Novartis AG raised its forecast as sales of blockbuster medicines for heart disease and psoriasis outpaced expectations, giving the stock its biggest boost in nine months." — Bernard Horn (Trades, Portfolio), Polaris Global Value Fund, Q2 2024 Fund Letter

Read full letter at gurufocus Bernard Horn's Polaris Global Value Fund 2nd-Quarter Letter 2024 Q2 page.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.